MiMedx Group Inc
$ 4.94
-6.44%
26 Feb - close price
- Market Cap 781,979,000 USD
- Current Price $ 4.94
- High / Low $ 5.42 / 4.80
- Stock P/E 19.56
- Book Value 1.61
- EPS 0.27
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.12 %
- ROE 0.19 %
- 52 Week High 8.46
- 52 Week Low 4.80
About
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Analyst Target Price
$9.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-29 | 2025-07-29 | 2025-04-28 | 2025-02-26 | 2024-10-30 | 2024-07-31 | 2024-04-30 | 2024-02-28 | 2023-10-30 | 2023-08-01 | 2023-05-02 | 2023-02-28 |
| Reported EPS | 0.15 | 0.1 | 0.05 | 0.07 | 0.05 | 0.12 | 0.07 | 0.32 | 0.06 | -0.0046 | -0.06 | -0.02 |
| Estimated EPS | 0.06 | 0.054 | 0.055 | 0.075 | 0.04 | 0.08 | 0.05 | 0.07 | 0.05 | -0.02 | -0.09 | -0.04 |
| Surprise | 0.09 | 0.046 | -0.005 | -0.005 | 0.01 | 0.04 | 0.02 | 0.25 | 0.01 | 0.0154 | 0.03 | 0.02 |
| Surprise Percentage | 150% | 85.1852% | -9.0909% | -6.6667% | 25% | 50% | 40% | 357.1429% | 20% | 77% | 33.3333% | 50% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.0929 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXG
2026-02-26 17:53:30
Shares of MiMedx Group (NASDAQ:MDXG) fell 8.8% on Thursday after the company released its Q4 and full-year results, which, despite beating EPS and revenue expectations, included 2026 revenue guidance below consensus. The guidance miss, suggesting potential deceleration due to reimbursement changes and slower adoption, overshadowed the positive Q4 performance, record adjusted EBITDA, and a new $100M share repurchase program. The stock experienced a significant drop in trading volume, indicating investor concerns about near-term growth.
2026-02-26 04:53:30
MiMedx Group reported record 2025 results with $419 million in net sales and nearly $106 million in adjusted EBITDA, driven by strong growth in both wound care and surgical segments. The company anticipates a near-term revenue pullback in Q1 2026 due to Medicare reimbursement changes in the wound-care market, guiding 2026 revenue to $340-$360 million. MiMedx is expanding its surgical portfolio and clinical evidence, including new product launches and a distribution agreement for a PRP system, while remaining disciplined in M&A with a share repurchase program in place.
2026-02-25 21:52:31
MiMedx Group, Inc. (MDXG) announced a Q4 adjusted EPS of $0.14 per share, significantly exceeding the FactSet estimate of $0.09. The company also reported Q4 revenue of $118.1 million, surpassing the FactSet estimate of $106.8 million. MiMedx specializes in placental biologics, developing and distributing tissue allografts for wound care and surgical applications.
2026-02-25 21:52:31
MiMedx Group Inc. (MDXG) reported fourth-quarter earnings of $15.2 million, or 10 cents per share, with adjusted earnings of 14 cents per share. The biomaterials developer posted $118.1 million in revenue for the quarter and $418.6 million for the full year, with a profit of $48.6 million. MiMedx anticipates full-year revenue to be between $340 million and $360 million.
2026-02-25 20:52:31
MIMEDX announced record operating and financial results for the fourth quarter and full year 2025, with net sales growing 27% year-over-year in Q4 and 20% for the full year. The company reported GAAP net income of $15 million in Q4 and Adjusted EBITDA of $29 million. MIMEDX also projected 2026 net sales between $340-360 million and authorized a $100 million share repurchase program, despite anticipated short-term disruptions from Medicare reimbursement changes.
2026-02-23 12:18:20
Several Wall Street analysts initiated coverage on various companies, providing bullish outlooks. Citizens analyst David Turkaly started coverage on MiMedx Group Inc. (NASDAQ: MDXG) with a Market Outperform rating and a $10 price target. Notable initiations also included York Space Systems Inc. (NYSE: YSS) by Baird and Raymond James, Ethos Technologies (NASDAQ: LIFE) by Goldman Sachs, and PicS N.V. (NASDAQ: PICS) by RBC Capital.
